364041-40-7

Upstream product

• 92817-88-4 (2S)-3-{[tert-butyl(diphenyl)silyl]oxy}-2-methylpropanal 
• 95514-04-8 (R)-3-(tert-butyldiphenylsilyloxy)-2-methylpropan-1-ol 
• 95514-03-7 (S)-3-(tert-butyl-diphenyl-silanyloxy)-2-methyl-propionic acid methyl ester 

Downstream Products

• 363610-61-1 (2S,3S,4S,5R)-1-(tert-Butyl-diphenyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-octadecan-5-ol 
• 363610-69-9 (2R,3R,4R,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-octadecanoic acid 
• 363610-68-8 (2S,3S,4R,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-octadecan-1-ol 
• 363610-64-4 Acetic acid (R)-1-[(1S,2S,3S)-4-hydroxy-2-(4-methoxy-benzyloxy)-1,3-dimethyl-butyl]-tetradecyl ester 
• 363610-60-0 (2S,3R,4S)-5-(tert-Butyl-diphenyl-silanyloxy)-3-(4-methoxy-benzyloxy)-2,4-dimethyl-pentan-1-ol 

Relevant academic research and scientific papers

Studies directed towards the synthesis of stevastelins - A macrolactonization approach to stevastelin B

A synthetic approach towards the cyclic depsipeptide immunosuppressant stevastelin B, based on the stereoselective synthesis of its propionate-derived fatty acid segment 6 that was coupled with the tripeptide 7 leading to the advanced stage acyclic intermediate 5, is described. In spite of our best efforts, the crucial macrolactonization reaction was not successful.